Compare JAZZ & TXRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | TXRH |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.0B |
| IPO Year | 2007 | 2004 |
| Metric | JAZZ | TXRH |
|---|---|---|
| Price | $169.65 | $166.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $194.40 | $189.47 |
| AVG Volume (30 Days) | ★ 1.6M | 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | N/A | ★ 12.56 |
| EPS | N/A | ★ 6.55 |
| Revenue | $4,157,832,999.00 | ★ $5,833,958,000.00 |
| Revenue This Year | $6.00 | $11.90 |
| Revenue Next Year | $6.84 | $10.41 |
| P/E Ratio | ★ N/A | $25.38 |
| Revenue Growth | 4.14 | ★ 14.40 |
| 52 Week Low | $95.49 | $148.73 |
| 52 Week High | $182.99 | $199.99 |
| Indicator | JAZZ | TXRH |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 44.55 |
| Support Level | $164.44 | $165.70 |
| Resistance Level | $182.75 | $178.68 |
| Average True Range (ATR) | 5.88 | 3.80 |
| MACD | -1.21 | -0.42 |
| Stochastic Oscillator | 34.58 | 3.70 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.